# Non-hydrolyzable acetyllysine analogs to study protein acetylation in vitro and in cells

**Authors:** Simon Maria Kienle, Matthias Sigg, Tobias Schneider, Katrin Stuber, Jan Lehmann, Jasmin Jansen, Florian Stengel, Andreas Marx, Michael Kovermann, Martin Scheffner

PMC · DOI: 10.1038/s41467-026-69782-6 · Nature Communications · 2026-02-21

## TL;DR

Researchers developed a stable acetyllysine analog to study protein acetylation effects in cells, overcoming limitations of natural acetylation.

## Contribution

A non-hydrolyzable acetyllysine analog, ketolysine (KeK), is introduced as a functional substitute for acetyllysine in cellular studies.

## Key findings

- Ketolysine (KeK) mimics acetyllysine (AcK) in structural and functional effects when incorporated into ubiquitin.
- KeK remains stable in cells, unlike AcK, which is deacetylated by deacetylases.
- KeK incorporation affects p53-mediated transcription, making it suitable for studying acetylation in vivo.

## Abstract

Lysine acetylation plays a prominent regulatory role in eukaryotic cells. Yet, determining the functional consequences of acetylation for a given protein represents a considerable challenge. For instance, lysine residues are subject to various posttranslational modifications, rendering interpretation of mutational studies difficult. The genetic code expansion technology enables site-specific incorporation of acetyllysine (AcK) into proteins, but the applicability of AcK is limited, as within cells, the acetyl group is removed by deacetylases. Here, we show that site-specific incorporation of the non-hydrolyzable AcK analog ketolysine (KeK) into ubiquitin closely resembles the structural and functional effects of AcK incorporation. Furthermore, AcK and KeK can be efficiently incorporated into the tumor suppressor p53 in cells. However, whereas AcK becomes deacetylated, KeK remains stable. Accordingly, incorporation of KeK, but not AcK, affects p53-mediated transcription. Thus, we propose that KeK is a well-suited AcK surrogate for studying acetylation of a given protein in cells.

Determining the consequences of acetylation for a protein of interest in cells is a considerable challenge. Using genetic code expansion and p53, this study shows that site-specific incorporation of non-hydrolysable acetyllysine analogues enables functional analysis.

## Linked entities

- **Genes:** TP53 (tumor protein p53) [NCBI Gene 7157]
- **Proteins:** CG11700 (uncharacterized protein), TP53 (tumor protein p53)
- **Chemicals:** acetyllysine (PubChem CID 92832), acetyl group (PubChem CID 177)

## Full-text entities

- **Genes:** TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, UBA1 (ubiquitin like modifier activating enzyme 1) [NCBI Gene 7317] {aka A1S9, A1S9T, A1ST, AMCX1, CFAP124, GXP1}, H3P16 (H3 histone pseudogene 16) [NCBI Gene 644914] {aka H3.6, H3F3AP6, p21}, FOXO4 (forkhead box O4) [NCBI Gene 4303] {aka AFX, AFX1, MLLT7}, TNK2 (tyrosine kinase non receptor 2) [NCBI Gene 10188] {aka ACK, ACK-1, ACK1, p21cdc42Hs}, BBC3 (BCL2 binding component 3) [NCBI Gene 27113] {aka JFY-1, JFY1, PUMA}, BLNK (B cell linker) [NCBI Gene 29760] {aka AGM4, BASH, BLNK-S, LY57, SLP-65, SLP65}, UBE2D2 (ubiquitin conjugating enzyme E2 D2) [NCBI Gene 7322] {aka E2(17)KB2, PUBC1, UBC4, UBC4/5, UBCH4, UBCH5B}, HDAC9 (histone deacetylase 9) [NCBI Gene 9734] {aka HD7, HD7b, HD9, HDAC, HDAC7B, HDAC9B}, ACSS2 (acyl-CoA synthetase short chain family member 2) [NCBI Gene 55902] {aka ACAS2, ACECS, ACS, ACSA, AceCS1, dJ1161H23.1}, HDAC2 (histone deacetylase 2) [NCBI Gene 3066] {aka HD2, KDAC2, RPD3, YAF1}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, TRNG (tRNA-Gly) [NCBI Gene 4563] {aka MTTG}, GLB1 (galactosidase beta 1) [NCBI Gene 2720] {aka EBP, ELNR1, MPS4B}, UCHL3 (ubiquitin C-terminal hydrolase L3) [NCBI Gene 7347] {aka UCH-L3}, SIRT2 (sirtuin 2) [NCBI Gene 22933] {aka SIR2, SIR2L, SIR2L2}
- **Diseases:** tumor (MESH:D009369), POI (MESH:D011488), PRM (MESH:D006967)
- **Chemicals:** H (MESH:D006859), HCl (MESH:D006851), Coomassie blue (MESH:C048139), MnCl2 (MESH:C025340), SDS (MESH:D012967), DTT (MESH:D004229), PBS (MESH:D007854), NAD (MESH:D009243), CaCl2 (MESH:D002122), carbenicillin (MESH:D002228), tricine (MESH:C100184), Lysine (MESH:D008239), biotin (MESH:D001710), acetate (MESH:D000085), 13C (MESH:C000615229), kanamycin (MESH:D007612), CoCl2 (MESH:C018021), AE (MESH:C538178), glucose (MESH:D005947), fluorine (MESH:D005461), IPTG (MESH:D007544), Q (MESH:D005973), CO2 (MESH:D002245), CuCl2 (MESH:C029892), nicotinamide (MESH:D009536), ATP (MESH:D000255), H2O (MESH:D014867), imidazole (MESH:C029899), amide (MESH:D000577), D2O (MESH:D017666), iodoacetamide (MESH:D007460), Peptides (MESH:D010455), amino acids (MESH:D000596), MgSO4 (MESH:D008278), nitrogen (MESH:D009584), urea (MESH:D014508), EDTA (MESH:D004492), His (MESH:D006639), thiamine (MESH:D013831), ZnCl2 (MESH:C016837), Lipofectamine 2000 (MESH:C086724), Nonidet P-40 (MESH:C010615), CO (MESH:D002248), polyacrylamide (MESH:C016679), Pefabloc (MESH:C002010), C (MESH:D002244), TFA (MESH:D014269), Triton X-100 (MESH:D017830), phenylalanine (MESH:D010649), MgCO3 (MESH:C005479), D-luciferin (MESH:C532924), FeCl3 (MESH:C024555), CoA (MESH:D003065), acetonitrile (MESH:C032159), NaCl (MESH:D012965), PA (MESH:D011478), 3H (MESH:D014316), crystal violet (MESH:D005840), desthiobiotin (MESH:C004749), leupeptin (MESH:C032854)
- **Species:** Methanosarcina mazei (species) [taxon 2209], Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606], Methanomethylophilus alvi (species) [taxon 1291540]
- **Mutations:** R273H, stop codon at position 11, K at position 11, K-to-Q, stop codon at position 120, C in 100, K by R
- **Cell lines:** BL21 (DE3) — Mus musculus (Mouse), Hybridoma (CVCL_B7HM), H1299 — Homo sapiens (Human), Lung large cell carcinoma, Cancer cell line (CVCL_0060), HEK293T — Homo sapiens (Human), Transformed cell line (CVCL_0063), E. coli B834 (DE3) — Rattus norvegicus (Rat), Rat insulinoma, Cancer cell line (CVCL_2G77)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12932645/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12932645/full.md

## References

2 references — full list in the complete paper: https://tomesphere.com/paper/PMC12932645/full.md

---
Source: https://tomesphere.com/paper/PMC12932645